Boehringer Ingelheim and Eli Lilly and Company have reported positive results from the MARLINA-T2D trial of Tradjenta (linagliptin) carried out in patients with type 2 diabetes (T2D) with a high risk of kidney impairment.
Tradjenta is a prescription medicine, which is used along with diet and exercise to reduce blood sugar level in adults with T2D.
The high levels of glucose can damage the kidney filters of a diabetic patient, which can later lead to kidney impairment.
Leakage of the protein albumin out of the kidneys into the urine signifies one of the first symptoms of damaged kidneys and early stage kidney disease and is termed as albuminuria.
The MARLINA-T2D trial included 360 patients with T2D and albuminuria and was designed to assess the safety and efficacy of Tradjenta versus placebo.
Helsinki University central hospital division of nephrology chief physician and nephrology professor and MARLINA-T2D trial principal investigator, Per-Henrik Groop, said: "Up to half of people with type 2 diabetes experience long-term problems with kidney function.
"Diabetes treatment options are generally limited for this group. These results support the use of Tradjenta, with just one dose for all patients, including those with type 2 diabetes who have early signs of kidney disease."
After 24 weeks, Tradjenta resulted to 0.6% reduction in A1C (a measure of average blood glucose over the past two to three months) against placebo.
According to urine albumin-to-creatinine ratio (UACR) measurement, change in albuminuria was not significant with Tradjenta versus placebo.
Throughout the study, Tradjenta displayed tolerability among the patients with a consistent renal safety profile.